β¨ Health Notices
22 DECEMBER 2005 NEW ZEALAND GAZETTE, No. 210 5369
Appointment of Compulsory Care Co-ordinators
Under section 140 of the Intellectual Disability (Compulsory Care and Rehabilitation) Act 2003, I appoint the following person as a compulsory care co-ordinator for the named geographical and operational area listed below.
Central Region including Manawatu-Wanganui, Palmerston North, Hawkeβs Bay, Wairarapa and Wellington:
Frank Ngatai.
The appointment takes effect on the date this notice is published in the New Zealand Gazette, and ends on 12 December 2010.
Dated at Wellington this 12th day of December 2005.
KAREN O. POUTASI (DR), Director-General of Health.
go8453
Medicines Act 1981
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: Fexofenadine
Active Ingredient: Fexofenadine hydrochloride 120mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Douglas Pharmaceuticals Limited
Manufacturer: Ranbaxy Laboratories Limited, Dewas, Madhya Pradesh, India
Product: Fexofenadine
Active Ingredient: Fexofenadine hydrochloride 180mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Douglas Pharmaceuticals Limited
Manufacturer: Ranbaxy Laboratories Limited, Dewas, Madhya Pradesh, India
Product: Inspra
Active Ingredient: Eplerenone 25mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Pfizer New Zealand Limited
Manufacturer: Pfizer Pharmaceuticals LLC, Caguas, Puerto Rico
Product: Inspra
Active Ingredient: Eplerenone 50mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Pfizer New Zealand Limited
Manufacturer: Pfizer Pharmaceuticals LLC, Caguas, Puerto Rico
Product: Venofer
Active Ingredient: Iron sucrose 540mg/mL equivalent to iron 20mg/mL
Dosage Form: Solution for injection
New Zealand Sponsor: Baxter Healthcare Limited
Manufacturer: ALTANA Pharma AG, Singen, Germany
Dated this 19th day of December 2005.
KAREN MITCHELL, Acting Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go8673
Renewal of Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Viramune
Active Ingredient: Nevirapine hemihydrate 10.35mg/mL equivalent 10mg/mL nevirapine
Dosage Form: Oral suspension
New Zealand Sponsor: Boehringer Ingelheim (NZ) Limited
Manufacturer: Boehringer Ingelheim Roxane Inc, Columbus, Ohio, United States of America
Note: This consent is valid for two years from 2 March 2006.
Dated this 19th day of December 2005.
KAREN MITCHELL, Acting Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go8672
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2005, No 210
Gazette.govt.nz —
NZ Gazette 2005, No 210
β¨ LLM interpretation of page content
π₯ Appointment of Compulsory Care Co-ordinator
π₯ Health & Social Welfare12 December 2005
Compulsory Care Co-ordinator, Appointment, Central Region, Intellectual Disability
- Frank Ngatai, Appointed Compulsory Care Co-ordinator
- Karen O. Poutasi (Dr), Director-General of Health
π₯ Consent to Distribution of New Medicines
π₯ Health & Social Welfare19 December 2005
Medicines, Distribution, Fexofenadine, Inspra, Venofer
- Karen Mitchell, Acting Deputy Director-General, Public Health
π₯ Renewal of Provisional Consent for New Medicine
π₯ Health & Social Welfare19 December 2005
Medicine, Provisional Consent, Viramune, Nevirapine
- Karen Mitchell, Acting Deputy Director-General, Public Health